ANX005 + Intravenous immunoglobulin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Guillain-Barré Syndrome
Conditions
Guillain-Barré Syndrome
Trial Timeline
Jan 29, 2020 → May 19, 2021
NCT ID
NCT04035135About ANX005 + Intravenous immunoglobulin
ANX005 + Intravenous immunoglobulin is a phase 1 stage product being developed by Annexon for Guillain-Barré Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04035135. Target conditions include Guillain-Barré Syndrome.
What happened to similar drugs?
0 of 1 similar drugs in Guillain-Barré Syndrome were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04035135 | Phase 1 | Completed |
Competing Products
1 competing product in Guillain-Barré Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Placebo + Intravenous immunoglobulin therapy | Chugai Pharmaceutical | Phase 3 | 32 |